Company intelligence
Eyconis, Inc
Deliver durable, life-changing therapies that improve vision for people living with serious eye disease
About Eyconis, Inc
Eyconis, a clinical-stage biotechnology company, is advancing next-generation, long-acting ophthalmic therapeutics. Through an exclusive worldwide license in ophthalmology from Ascendis Pharma (NASDAQ: ASND), Eyconis is utilizing the commercially validated TransCon technology platform to develop therapies that have the potential to improve disease control and visual outcomes in people with serious eye disease. Eyconis’ lead program, EYC-0305, is being developed as a long-acting anti-VEGF therapy for wet age-related macular degeneration, with potential applicability across other retinal diseases including diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. Beyond EYC-0305, Eyconis is developing a broader pipeline of long-acting therapies across other ophthalmic indications with significant unmet need. For more information, visit www.eyconis.com.
Verified activity
Signals from Eyconis, Inc
1 published signal